Management Team

CHO Pharma is composed of a number of international professionals with experience in management and pharmaceutical R&D. Currently, more than 40 scientists with expertise in carbohydrate-based technology and biopharmaceutical development are working in the company, and we are in the process of expansion by recruiting the best professionals and scientists to join the company. The following are some key members.

Chairman      Chao-Long Chen,MD,PhD (Hon.)

Professor Chao-Long Chen is a pioneer liver transplant surgeon who performed the first successful liver transplantation in Asia in 1984, and by 2017, has accomplished 1700 more. He is a graduate of the Kaohsiung Medical University and did his surgical training at the Chang Gung Memorial Hospital, Taiwan and the Hospital for Sick Children, Toronto, Canada. He later obtained fellowship training in liver transplantation with the renowned Professor Thomas Starzl at the University of Pittsburgh, USA. He is a recipient of various honors and distinctions, both locally and internationally. He became Professor of Surgery in 1993 and subsequently has been bestowed with Honorary PhD and Professor by acclaimed international universities. In 1994, he performed the first living donor liver transplantation in Taiwan and was bestowed with the National Award for Outstanding Contribution in Science and Technology in 1996. He did the first split liver transplantation in Asia in 1997. He started the adult living donor liver transplantation in Taiwan in 1999. Further, he performed the first dual graft living donor liver transplantation in Taiwan in 2002, has pioneered routine microsurgical biliary reconstruction in the world in 2006 and performed the first segment 2 monosegment living donor liver transplantation in Taiwan in 2013. He became Superintendent of the Kaohsiung Chang Gung Memorial Hospital in 2003-2015 and has become Superintendent Emeritus since October 2015. He has published more than 460 SCI-cited scientific articles and has lectured in more than 300 international and overseas congresses, and honorary and visiting professorships. He was appointed in the advisory board of Center for Asia Pacific Policy of USA based RAND Corporation in 2016. He is an associate editor of the American Journal of Transplantation and serves in the editorial board of Annals of Surgery, Transplantation, Liver Transplantation, etc. He was elected as Academician of the prestigious Chinese Academy of Engineering in 2007 and as President-elect of the International Living Donor Liver Transplantation Study Group in 2017. He remains director of one of the leading global centers in living donor liver transplantation.

Senior Technology Advisor Lan-Bo Chen, Ph.D.

Dr. Chen is Professor Emeritus of Pathology at Harvard Medical School. He received his B.S. in chemistry from National Taiwan University, Ph.D. in cell biology from the Massachusetts Institute of Technology, postdoctoral training under Dr. James D. Watson (Nobel Laureate) at Cold Spring Harbor Laboratories, was recruited by Dr. Baruj Benacerraf (Nobel Laureate) to Harvard Medical School and elected as an academician of the Academia Sinica of Taiwan. He is the author of over 250 academic publications and is the founder of several successful biotechnology companies and ventures, including Fuji ImmunoPharmaceuticals Corp. and Shionogi BioResearch Corp. (both with Nobel laureate Dr. Susumu Tonegawa); Caxton Life Science Partners; Taiwan Global BioFund; TaiMed Biologics; Mevion Medical Systems; Cancer BioScience; Cancer Genetics; Kava Pharmaceuticals; SinglePixel BioMedical; Quercegen Pharma; Madrigal/Synta Pharmaceuticals and Sequential Medicine. Dr. Chen has served as a Senior Consultant for numerous large pharmaceutical firms, and has led the development or consulted for more than a dozen drugs and drug candidates.

President      Mr. Horng-Dar Lin

Horng-Dar Lin is the President at CHO Pharma, where he is responsible for the company’s operation including strategic planning, global business development, partnership and expansion. Prior to CHO Pharma, Horng-Dar was a partner at Winston & Strawn and used to serve as a Vice President at Foxconn Technology Group. His experience includes managing an IP/Legal team with total staff of 450 people, stipulating patent strategy, leading global technology transfer and negotiation, handling IP/technology disputes and litigation, etc. He was the lead counsel in several IPO projects and is also renowned for his legal expertise in handling large scale multinational transactions, including acquiring several US and Japanese companies. Before his careers in private sector, Horng-Dar was a Judge at Taiwan Taipei District Court. Horng-Dar brings more than 20 years of extensive experience and expertise to CHO Pharma, leading the team to expedite the product development and the commercialization of the company’s platform technology. Horng-Dar received his B.S. in Chemistry from National Taiwan University and obtained his Master of Laws degrees from both Soochow University and Columbia University. Horng-Dar is an attorney admitted to Taiwan and New York State.

Executive Vice President      Dr. Chung-Yi Wu

Dr. Chung-Yi Wu obtained his Ph.D. degree from the Department of Applied Chemistry at National Chiao Tung University. He joined Academician Chi-Huey Wong’s lab for his postdoctoral research. In 2006, Dr. Wu accepted a position as an assistant research fellow at the Genomic Research Center in Academia Sinica to continue his research in glycoscience and obtained his position as research fellow in 2016. During this period, Dr. Wu published more than 100 academic papers and was granted for more than 40 patents. His achievements garnered him prestigious awards such as the 2014 American Chemical Society David Y. Gin New Investigator Award, Taiwan Bio-Development Foundation Lecturer Scholar Award, and National Chiao Tung University Applied Chemistry Department Distinguished Alumnus Award. Moreover, Dr. Wu is the main contributor of the more than 20 patents in the field of homogenous antibody, glycoprotein, glycovaccine, and glycoarray technologies that were transferred from Academia Sinica to our company.